"Dr. Bryan Doner, DO, CHWS, FACHM, Lead Principal Investigator said: As the lead principal investigator for the previous ZEL-007 clinical study, I am delighted to successfully complete this groundbreaking clinical research and the unveiling of its topline data analysis. The implications of these results for patients are incredibly promising and thrilling. Through this rigorously designed study, we have demonstrated that ZLT-L-007 is a safe, effective, and well-tolerated alternative for patients who would typically seek a Lyrica® level of pain relief. I am particularly pleased that the topline data reveals no reported serious adverse events, and participants’ blood pressure and other safety vitals remained unaffected throughout. This confirms that ZLT-L-007 is a well tolerated product that delivers statistically significant pain relief, surpassing the levels achieved by Lyrica.® These findings not only contribute to the advancement of research in the cannabinoid pharmaceutical industry but also hold immense significance in enhancing patient care by informing future studies and treatment optimisation."
GL
ZLD Price at posting:
$2.16 Sentiment: Buy Disclosure: Held
